Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 78 publications
BIO26-040: MTAP Deficiency in Thoracic Oncology: Bridging Genomic Loss, Survival Deficits, and Immunosuppressive Microenvironments.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
International Consensus on Severe Lung Cancer-The Second Edition.
Journal: Translational lung cancer research
Published: March 21, 2026
The COCOON trial: wrapping potent EGFR therapy in proactive supportive care.
Journal: Journal of thoracic disease
Published: February 19, 2026
Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck Malignancies.
Journal: Cancers
Published: January 31, 2026
Successful Tarlatamab Rechallenge After Recurrent High-Grade Cytokine Release Syndrome in Chromothripsis-Mediated SCLC: A Case Report.
Journal: JTO clinical and research reports
Published: December 29, 2025
Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).
Journal: Current oncology reports
Published: September 14, 2025
Time toxicity in previously untreated metastatic or unresectable epidermal growth factor receptor-mutant non-small cell lung cancer: a clinical practice review.
Journal: Translational lung cancer research
Published: June 20, 2025
Clinically Explainable Prediction of Immunotherapy Response Integrating Radiomics and Clinico-Pathological Information in Non-Small Cell Lung Cancer.
Journal: Cancers
Published: June 10, 2025
SUPE_R Surveillance? PET/CT in Post-Treatment NSCLC and the Imperative of Proof Before Practice.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 08, 2025
HSR25-147: Time Toxicity of Different Frontline Regimens in EGFR Mutated Non-Small Cell Lung Cancer.
HSR25-147: Time Toxicity of Different Frontline Regimens in EGFR Mutated Non-Small Cell Lung Cancer.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 27, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.
Journal: The Lancet. Oncology
Published: February 28, 2025
Last Updated: 09/26/2026